# Testing the Combination of Anti-cancer Drugs Atezolizumab and Tiragolumab in People With Advanced Stage Rare Cancers, RARE3 Trial

> **NCT05715281** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 12 (actual)

## Conditions studied

- Advanced Rare Malignant Solid Neoplasm
- Rare Malignant Solid Neoplasm
- Refractory Rare Malignant Solid Neoplasm

## Interventions

- **BIOLOGICAL:** Atezolizumab
- **PROCEDURE:** Biopsy Procedure
- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Computed Tomography
- **PROCEDURE:** Echocardiography Test
- **DRUG:** Tiragolumab

## Key facts

- **NCT ID:** NCT05715281
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-09-26
- **Primary completion:** 2025-10-06
- **Final completion:** 2026-11-21
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2025-11-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05715281

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05715281, "Testing the Combination of Anti-cancer Drugs Atezolizumab and Tiragolumab in People With Advanced Stage Rare Cancers, RARE3 Trial". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05715281. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*